Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 2 2Sarcoma 1Neuroma, Acoustic 1Neurilemmoma 1Neoplasm Metastasis 1Multiple Myeloma 1Meningioma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 5Everolimus 4Sirolimus 2Lapatinib 2HDAC-42 2vistusertib 1temsirolimus 1neratinib 1icotinib 1emvododstat 1brolucizumab 1brigatinib 1aflibercept 1Vascular Endothelial Growth Factor A 1Valproic Acid 1Sunitinib 1Magnetic Resonance Imaging 1Immunoglobulin G 1Endostatins 1Doxycycline 1Disulfides 1Crizotinib 1Cetuximab 1Axitinib 1Aspirin 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neurofibromatosis 2 × HDAC-42 × Clear all
NCT02282917 2025-12-05

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Massachusetts Eye and Ear Infirmary

Phase EARLY_PHASE1 Terminated
7 enrolled 19 charts
CNS

Meningioma, Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated
25 enrolled
CNS

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡